Objective:

The article presents Erik Vaessen’s perspective on manufacturing challenges for cell and gene therapies, including scale-up, process development, and approaches that may support commercial production.

Approach:

• Source: Interview with Erik Vaessen, Chief Business Officer at FUJIFILM Biosciences.
• Focus: Manufacturing costs, process development, technology transfer, automation, supply chains, and future manufacturing strategies.

Key Findings:

• High cost of goods, complex workflows, specialized labor, and biological variability complicate commercial-scale production.
• Developers increasingly consider scalability, manufacturability, supply-chain robustness, and commercial viability earlier in development.
• Technology transfer, reproducibility, operator training, raw-material variability, documentation, and GMP execution can make scale-up more difficult than expected.
• Advances in cell-culture media and process development can support cell growth, productivity, and consistency across scales.
• Vaessen identifies improved therapy efficacy, automation, and reliable supplies of media, buffers, and reagents as factors that could help address cost and scale challenges.
• In vivo cell and gene therapies, including in vivo CAR-T and self-amplifying RNA approaches, may shift some manufacturing toward biologics and nucleic-acid platforms.

Interpretation:

Vaessen emphasizes planning for commercial manufacturing from the outset, with attention to transferability, process robustness, and supply-chain needs.

Limitations:

• The material is an interview presenting one industry executive’s perspective.
• The supplied context does not include quantitative estimates of manufacturing costs or efficiency.

Conclusion:

The interview describes early process development, automation, consistent inputs, and emerging manufacturing strategies as important considerations for scaling cell and gene therapies.

Sources:

• Article context provided in the prompt